14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
VTOL vs SRTA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Bristow Group Inc. (VTOL) is the stronger overall head-to-head candidate over Strata Critical Medical, Inc. (SRTA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VTOL carries a Unified Composite Score of 46.7/100 (HOLD) at $39.27 (8.8x Forward P/E, 10.6% operating margin), whereas SRTA carries 32.7/100 (SELL) at $5.26 (69.9x Forward P/E, -4.7% operating margin).
Growth vs. Quality Trade-Off: VTOL earns the overall head-to-head edge with a stronger Unified Composite Score (46.7/100 HOLD vs. SRTA 32.7/100 SELL) and 0.48β · 43% Vol risk profile, whereas SRTA leads top-line expansion (+50.3% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: VTOL is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.2); meanwhile SRTA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 52.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Care Facilities value chain with $492.2M market capitalization and -4.7% operating margin.
OpEx & R&D Reinvestment26.3% of Rev ($74M)
90D Engineering Disclosures0 Published
Investor FAQ VTOL vs SRTA Key Questions & Quantitative Answers
As of Nov 17, 2026, Bristow Group Inc. (VTOL) is the stronger overall head-to-head candidate over Strata Critical Medical, Inc. (SRTA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VTOL carries a Unified Composite Score of 46.7/100 (HOLD) at $39.27 (8.8x Forward P/E, 10.6% operating margin), whereas SRTA carries 32.7/100 (SELL) at $5.26 (69.9x Forward P/E, -4.7% operating margin). Growth vs. Quality Trade-Off: VTOL earns the overall head-to-head edge with a stronger Unified Composite Score (46.7/100 HOLD vs. SRTA 32.7/100 SELL) and 0.48β · 43% Vol risk profile, whereas SRTA leads top-line expansion (+50.3% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VTOL is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.2); meanwhile SRTA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 52.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SRTA leads the Growth & Scale pillar: VTOL posts +13.4% YoY revenue growth and -45.9% YoY earnings growth on $1.62B TTM revenue (27.8% gross margin, 10.6% operating margin), compared with SRTA at +50.3% YoY revenue growth and +0.0% YoY earnings growth on $281M TTM revenue (21.6% gross margin, -4.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VTOL cumulative revenue shifted +577.3% while SRTA shifted +566.7%. In operating R&D and SG&A reinvestment, VTOL deploys 17.2% of Rev ($278M) (0 90-day corporate R&D disclosures) versus 26.3% of Rev ($74M) (0 disclosures) for SRTA.
VTOL screens cheaper on headline valuation multiples. VTOL trades at 8.8x Forward P/E, 15.0x Trailing P/E, N/M PEG, and 1.2x EV/Revenue (0.8% FCF margin), whereas SRTA trades at 69.9x Forward P/E, 138.9x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (-0.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTOL (7.6% ROE) versus SRTA (-7.5% ROE) capital efficiency.
In options market volatility and institutional positioning, VTOL carries 154.9% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.48β · 43% Vol realized risk). By comparison, SRTA carries 61.9% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.95β · 80% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.